- Sections
- C - Chimiemétallurgie
- C07K - Peptides
- C07K 14/01 - Virus à ADN
Détention brevets de la classe C07K 14/01
Brevets de cette classe: 309
Historique des publications depuis 10 ans
|
13
|
11
|
11
|
10
|
20
|
11
|
27
|
14
|
17
|
2
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Flagship Pioneering Innovations V, Inc. | 219 |
9 |
| The Institute of Biophysics of The Chinese Academy of Sciences | 11 |
6 |
| Guangdong Lanyu Biotechnology Co., Ltd. | 6 |
6 |
| Deutsches Krebsforschungszentrum | 408 |
5 |
| The University of North Carolina at Chapel Hill | 2067 |
5 |
| The General Hospital Corporation | 4797 |
4 |
| Kaneka Corporation | 4635 |
4 |
| Mitsui & Co., Ltd. | 50 |
4 |
| Proclara Biosciences, Inc. | 8 |
4 |
| Rakuno Gakuen University | 16 |
4 |
| Boehringer Ingelheim Vetmedica, Inc. | 105 |
3 |
| The Johns Hopkins University | 5796 |
3 |
| EpiVax, Inc. | 68 |
3 |
| NeuroPhage Pharmaceuticals, Inc. | 5 |
3 |
| The University of Tokyo | 4318 |
3 |
| ContraFect Corporation | 62 |
3 |
| Massey Ventures Limited | 15 |
3 |
| Othair Prothena Limited | 35 |
3 |
| The Regents of the University of California | 20473 |
2 |
| Genentech, Inc. | 4052 |
2 |
| Autres propriétaires | 230 |